New data shows benefit of drug combination for metastatic castration resistant prostate cancer

By | September 19, 2021
New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer (mCRPC).